arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Skye Bioscience, Inc.

SKYE
$1.05 ▼ -0.08 (-7.46%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
61 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Skye Bioscience, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $41.7M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 2224.9% ↗
FCF / Share $-0.18 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

61-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-12.51M
↓ -12.7% —
FCF / Share Free cash flow per share
$-0.18
↑ +16.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
0
Cash Quality →
52

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 15 years · 61 quarters